BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Iptacopan: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Novartis Pharmaceuticals. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-30 est. | P2 | Novartis Pharmaceuticals NVS | NCT06388941 Iptacopan in Patients With ANCA Associated Vasculitis | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | active not recruiting | 84 |
| 2027-01-29 est. | P3 | Novartis Pharmaceuticals NVS | NCT04817618 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | C3G | recruiting | 98 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08-19 | P2 | Novartis Pharmaceuticals NVS | NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Age-Related Macular Degeneration | completed | 168 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.